炬華科技(300360.SZ):嘉興炬華聯昕擬583萬元受讓正盈資本所持普頌電子33.33%股權
格隆匯 8 月 4日丨炬華科技(300360.SZ)公佈,近日,嘉興炬華聯昕與杭州正盈資本投資管理合夥企業(有限合夥)(以下簡稱“正盈資本”)簽署了《股權轉讓協議》,嘉興炬華聯昕擬以自有資金人民幣583萬元受讓正盈資本持有的深圳市普頌電子有限公司(以下簡稱“普頌電子”)33.3333%的股權。定價依據經具有證券期貨評估業務資格的坤元資產評估有限公司的評估為基準確定,本次評估最終採用市場法評估結論作為普頌電子股東全部權益的評估值,普頌電子股東全部權益的評估價值為1,750萬元。交易完成後,嘉興炬華聯昕持有普頌電子33.3333%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.